Levin Capital Strategies’s Coherus Oncology CHRS Stock Holding History

Levin Capital Strategies’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-30,000	Closed	-$128K	–	282
2023 Q2	$128K	Buy	+30,000	New	+$177K	0.01%	237

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Levin Capital Strategies's CHRS Position: Q3 2023 in Review

Levin Capital Strategies sold out of Coherus Oncology (CHRS) in Q3 2023, closing a stake of 30,000 shares — an estimated $128K sold.

Levin Capital Strategies first reported a position in CHRS in Q2 2023 and held it in 1 quarter. The position peaked at $128K in Q2 2023. 169 funds tracked by Wall St. Rank hold CHRS as of Q3 2023.

Levin Capital Strategies reported no remaining Coherus Oncology position as of Q3 2023 after selling out during the quarter.
Levin Capital Strategies sold 30,000 Coherus Oncology shares in Q3 2023, an estimated $128K.
Levin Capital Strategies first reported a position in Coherus Oncology in Q2 2023 and held it in 1 quarter.
Levin Capital Strategies's Coherus Oncology position peaked at $128K in Q2 2023.
169 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2023.

Based on Levin Capital Strategies's 13F filing for Q3 2023, filed 31 Oct 2023.